Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    AGN

No quotes available
-- USD   0.00%
07/27 Teva, Allergan win U.S. antitrust approval for generics deal
07/27 ALLERGAN : Teva expect to close $40.5B Allergan generic deal next we..
07/26 ALLERGAN : Receives Positive Opinion For Truberzi (Eluxadoline) For ..
SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Allergan : Establishment Labs Expands Senior Leadership Team

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/27/2016 | 11:51pm CEST

New York, NY (PRWEB) July 27, 2016

Establishment Labs, a global medical device company focused on breast implant technologies with a strong emphasis on product development and innovation, is pleased to announce the expansion of its global marketing team with two key hires. Jane Wolf has joined the company as Vice President of Global Marketing, and Kristine Halls is now Associate Director of Global Marketing.

"We are very pleased to welcome both Jane and Kristine to our marketing team. Jane brings extensive experience in strategic planning and successfully launching new products. As we continue to expand our product portfolio and seek FDA approval, her disciplined marketing experience will be of critical importance to our success," said Juan José Chacón-Quirós, CEO of Establishment Labs. "Kristine's tenure at Allergan will be an invaluable resource. We plan to leverage her strategic thinking and brand marketing skills from previous breast implant launches immediately."

Ms. Wolf most recently headed up the commercial launch of Kybella™, a first-in-class entrant into the aesthetic market while at Kythera Biopharmaceuticals. Previously, she spent over 25 years at Allergan where she held positions of increasing responsibility in sales leadership and U.S. and global marketing. Ms. Wolf worked in Allergan's eye care division, as well as in strategic marketing, where she led the competitive offensive strategy of BOTOX® to maintain its leading global market share.

"It's exciting to join an organization like Establishment Labs whose range of differentiated products offers unique solutions in safety and aesthetic outcomes to both consumers and surgeons," commented Ms. Wolf. "Motiva Implants® has already been quite successful, and I look forward to building Establishment Labs' marketing capabilities to expand into new markets and bring them to the U.S."

Ms. Halls brings significant marketing experience from her work at Bayer Healthcare, Johnson and Johnson, Neutrogena and Allergan. Most recently, Ms. Halls worked on breast aesthetics at Allergan, focusing on the Natrelle® Breast Portfolio.

About Establishment Labs:
Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (http://www.motivaimplants.com). Utilizing only the highest quality of medical grade silicones, CE-marked Motiva Implants® are rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.

Read the full story at http://www.prweb.com/releases/2016/07/prweb13581165.htm

(c) 2016 PRWEB.COM Newswire, source Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN, INC.
07/27 ALLERGAN : Establishment Labs Expands Senior Leadership Team
07/27 Teva, Allergan win U.S. antitrust approval for generics deal
07/27 ALLERGAN : Teva expect to close $40.5B Allergan generic deal next week
07/27 ALLERGAN PLC : Other Events (form 8-K)
07/27 ALLERGAN : Assigned Patent
07/26 ALLERGAN : Receives Positive Opinion For Truberzi (Eluxadoline) For Treatment Of..
07/26 ALLERGAN : Allergen receives positive opinion for IBS drug
07/26 ALLERGAN : Gets CHMP Positive Opinion For Truberzi To Treat IBS-D In Adults
07/23 ADAMIS PHARMACEUTICALS : Provides Update On License Agreement with Allergan plc
07/20 Allergan and Adamas Announce New Expanded Indication for NAMZARIC (Memantine ..
More news
Sector news : Pharmaceuticals - NEC
07/27 Teva, Allergan win U.S. antitrust approval for generics deal
07/27DJTEVA PHARMACEUTICAL : Correction to Teva, Allergan Article
07/27DJRenault Board Cuts CEO's 2016 Pay After Spat With Shareholders
07/27DJALERE : Faces Criminal Probe Over Medicare, Medicaid Billing -- Update
07/27DJALERE : Faces Criminal Probe Over Medicare, Medicaid Billing -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 MANNKIND : A Head Pain Gain Or A Pocket-Book Drain?
2015 Tracking Dan Loeb's Third Point Portfolio - Q1 2015 Update
2015 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2015 Update
2015 Time Warner Is A Buy - Cramer's Lightning Round (5/21/15)
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
Ambrose Robert Douglas Bailey Chairman & President
Scott M. Whitcup Chief Scientific Officer & Executive VP-Research
Raymond H. Diradoorian Executive VP-Global Technical Operations
Maria Teresa Hilado Director
Joann Bradley Investor Relations Contact
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN, INC.13.00%0
JOHNSON & JOHNSON21.84%344 243
PFIZER INC.14.10%223 368
NOVARTIS AG-5.30%219 971
ROCHE HOLDING LTD.-9.99%218 902
MERCK & CO., INC.10.49%161 542
More Results